Alex Yu

532 total citations
18 papers, 196 citations indexed

About

Alex Yu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pharmaceutical Science. According to data from OpenAlex, Alex Yu has authored 18 papers receiving a total of 196 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Pharmaceutical Science. Recurrent topics in Alex Yu's work include Prostate Cancer Treatment and Research (5 papers), Drug Solubulity and Delivery Systems (4 papers) and Statistical Methods in Clinical Trials (4 papers). Alex Yu is often cited by papers focused on Prostate Cancer Treatment and Research (5 papers), Drug Solubulity and Delivery Systems (4 papers) and Statistical Methods in Clinical Trials (4 papers). Alex Yu collaborates with scholars based in United States, Belgium and Canada. Alex Yu's co-authors include Duxin Sun, Bo Wen, Jason Baker, William L. Hasler, Mark J. Koenigsknecht, Gordon L. Amidon, Yasuhiro Tsume, Xinyuan Zhang, Robert Lionberger and Manjunath P. Pai and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Alex Yu

17 papers receiving 193 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alex Yu United States 7 74 51 41 34 25 18 196
Claire Patterson United Kingdom 6 91 1.2× 29 0.6× 98 2.4× 14 0.4× 15 0.6× 8 270
Emilija Janevik-Ivanovska North Macedonia 7 94 1.3× 43 0.8× 51 1.2× 39 1.1× 10 0.4× 23 350
Martin Mueller‐Zsigmondy Switzerland 7 116 1.6× 55 1.1× 58 1.4× 54 1.6× 30 1.2× 8 239
Julie K. Rhie United States 9 59 0.8× 77 1.5× 54 1.3× 11 0.3× 17 0.7× 12 208
Ann Fioritto United States 6 60 0.8× 201 3.9× 23 0.6× 167 4.9× 16 0.6× 10 322
Marcus Westerberg Sweden 12 147 2.0× 95 1.9× 35 0.9× 170 5.0× 23 0.9× 39 374
Pirjo Nykänen Finland 8 142 1.9× 65 1.3× 109 2.7× 335 9.9× 21 0.8× 14 548
Marius Monschke Germany 10 145 2.0× 90 1.8× 232 5.7× 22 0.6× 30 1.2× 11 393
Ditte M. Karpf Denmark 10 89 1.2× 43 0.8× 41 1.0× 7 0.2× 9 0.4× 16 268
James E. Huckle United States 8 32 0.4× 20 0.4× 48 1.2× 30 0.9× 9 0.4× 11 233

Countries citing papers authored by Alex Yu

Since Specialization
Citations

This map shows the geographic impact of Alex Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alex Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alex Yu more than expected).

Fields of papers citing papers by Alex Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alex Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alex Yu. The network helps show where Alex Yu may publish in the future.

Co-authorship network of co-authors of Alex Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Alex Yu. A scholar is included among the top collaborators of Alex Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alex Yu. Alex Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
3.
Morris, Michael J., Jeffrey Y.C. Wong, Luke T. Nordquist, et al.. (2024). A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(16_suppl). 5010–5010. 7 indexed citations
4.
Yu, Alex, et al.. (2023). Bioequivalence clinical trial simulation: a case study of apalutamide administered in applesauce versus whole tablets. SHILAP Revista de lepidopterología. 9(1). 2 indexed citations
5.
Yu, Alex, et al.. (2023). Bioequivalence of 240 mg Apalutamide Tablets and Preparation in Aqueous Food Vehicles for Alternative Administration. Clinical Pharmacology in Drug Development. 13(4). 432–439.
6.
Morris, Michael J., Oliver Sartor, Jeffrey Y.C. Wong, et al.. (2022). Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer.. Journal of Clinical Oncology. 40(16_suppl). TPS5104–TPS5104. 1 indexed citations
7.
Saad, Fred, Kim N., Neal D. Shore, et al.. (2021). Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE). Cancer Chemotherapy and Pharmacology. 88(1). 25–37. 23 indexed citations
8.
Yu, Alex, et al.. (2021). Pharmacokinetics and Use‐Testing of Apalutamide Prepared in Aqueous Food Vehicles for Alternative Administration. Clinical Pharmacology in Drug Development. 10(11). 1375–1384. 4 indexed citations
9.
Yu, Alex, Mark J. Koenigsknecht, Bart Hens, et al.. (2019). Mechanistic Deconvolution of Oral Absorption Model with Dynamic Gastrointestinal Fluid to Predict Regional Rate and Extent of GI Drug Dissolution. The AAPS Journal. 22(1). 3–3. 6 indexed citations
10.
Li, Feng, Hebao Yuan, Huixia Zhang, et al.. (2019). Neonatal Fc Receptor (FcRn) Enhances Tissue Distribution and Prevents Excretion of nab-Paclitaxel. Molecular Pharmaceutics. 16(6). 2385–2393. 10 indexed citations
11.
Yu, Alex. (2018). A Novel Mechanistic and Physiologically-Based Pharmacokinetic Model with Dynamic Gastrointestinal Fluid Transport. Deep Blue (University of Michigan). 1 indexed citations
12.
Li, Feng, Huixia Zhang, Miao He, et al.. (2018). Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety Profiles. Molecular Pharmaceutics. 15(10). 4505–4516. 19 indexed citations
13.
Koenigsknecht, Mark J., Jason Baker, Bo Wen, et al.. (2017). In Vivo Dissolution and Systemic Absorption of Immediate Release Ibuprofen in Human Gastrointestinal Tract under Fed and Fasted Conditions. Molecular Pharmaceutics. 14(12). 4295–4304. 45 indexed citations
14.
Yu, Alex, Trachette L. Jackson, Yasuhiro Tsume, et al.. (2017). Mechanistic Fluid Transport Model to Estimate Gastrointestinal Fluid Volume and Its Dynamic Change Over Time. The AAPS Journal. 19(6). 1682–1690. 23 indexed citations
15.
16.
Yu, Alex, Jason Baker, Ann Fioritto, et al.. (2016). Measurement of in vivo Gastrointestinal Release and Dissolution of Three Locally Acting Mesalamine Formulations in Regions of the Human Gastrointestinal Tract. Molecular Pharmaceutics. 14(2). 345–358. 42 indexed citations
17.
Yu, Alex, et al.. (2011). Economic evaluation of denosumab compared with zoledronic acid in patients with hormone-refractory prostate cancer with bone metastases.. Journal of Clinical Oncology. 29(15_suppl). e15115–e15115. 4 indexed citations
18.
Goldberg, David M., M. Waheed Roomi, & Alex Yu. (1982). Modulation by phenobarbital of lipolytic activity in postheparin plasma and tissues of the rat. Canadian Journal of Biochemistry. 60(11). 1077–1083. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Claire Patterson Breakdown of academic impact, for papers by Emilija Janevik-Ivanovska Breakdown of academic impact, for papers by Martin Mueller‐Zsigmondy Breakdown of academic impact, for papers by Julie K. Rhie Breakdown of academic impact, for papers by Ann Fioritto Breakdown of academic impact, for papers by Marcus Westerberg Breakdown of academic impact, for papers by Pirjo Nykänen Breakdown of academic impact, for papers by Marius Monschke Breakdown of academic impact, for papers by Ditte M. Karpf Breakdown of academic impact, for papers by James E. Huckle
Rankless by CCL
2026